Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Vij

Showing results (61-70 of 283) with videos related to

Pageof 29
Sort By:
Plos One|July 5, 2013
Germinal center B-cells resist transformation by Kras independently of tumor suppressor ArfChelsea D Mullins, Mack Y Su, Vishwanathan Hucthagowder, et al.
Annals of Hematology|March 5, 2020
DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myelomaScott R Goldsmith, Mark A Fiala, Brandon Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 16, 2015
Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple MyelomaMark A Fiala, Joseph D Finney, Keith E Stockerl-Goldstein, et al.
American Journal of Hematology|August 29, 2009
An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myelomaRavi Vij, Noemi Horvath, Andrew Spencer, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 31, 2019
A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple MyelomaArmin Ghobadi, Mark A Fiala, Michael Rettig, et al.
Biomaterials|September 25, 2015
3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myelomaPilar de la Puente, Barbara Muz, Rebecca C Gilson, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 18, 2014
Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patientsRavi Vij, Amitabha Mazumder, Mark Klinger, et al.
Leukemia & Lymphoma|February 1, 2017
Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myelomaDan T Vogl, Thomas G Martin, Ravi Vij, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 7, 2017
Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell CollectionAmanda F Cashen, Michael Rettig, Feng Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström MacroglobulinemiaIrene M Ghobrial, Ravi Vij, David Siegel, et al.
Pageof 29

Showing results (61-70 of 283) with videos related to

Sort By:
Pageof 29
Plos One|July 5, 2013
Germinal center B-cells resist transformation by Kras independently of tumor suppressor ArfChelsea D Mullins, Mack Y Su, Vishwanathan Hucthagowder, et al.
Annals of Hematology|March 5, 2020
DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myelomaScott R Goldsmith, Mark A Fiala, Brandon Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 16, 2015
Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple MyelomaMark A Fiala, Joseph D Finney, Keith E Stockerl-Goldstein, et al.
American Journal of Hematology|August 29, 2009
An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myelomaRavi Vij, Noemi Horvath, Andrew Spencer, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 31, 2019
A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple MyelomaArmin Ghobadi, Mark A Fiala, Michael Rettig, et al.
Biomaterials|September 25, 2015
3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myelomaPilar de la Puente, Barbara Muz, Rebecca C Gilson, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 18, 2014
Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patientsRavi Vij, Amitabha Mazumder, Mark Klinger, et al.
Leukemia & Lymphoma|February 1, 2017
Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myelomaDan T Vogl, Thomas G Martin, Ravi Vij, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 7, 2017
Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell CollectionAmanda F Cashen, Michael Rettig, Feng Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström MacroglobulinemiaIrene M Ghobrial, Ravi Vij, David Siegel, et al.
Pageof 29